

11th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

BUDAPEST, 09 -11 NOVEMBER, 2011



www.ifmad.org

CHAIRMAN: Siegfried KASPER (Austria)

CO-CHAIRMAN: Stuart A. MONTGOMERY (United Kingdom)



Final Programme



SCIENTIFIC COMMITTEE

Chairman

Siegfried Kasper (*Austria*)

Co-Chairman

Stuart A. Montgomery (*United Kingdom*)

Scientific Advisers

C. Allgulander (*Sweden*), C.A. Altamura (*Italy*), C. Arango (*Spain*),
D. Baldwin (*United Kingdom*), M. Bauer (*Germany*), P. Boyer (*Canada*),
G. Burrows (*Australia*), G.B. Cassano (*Italy*), K. Demyttenaere (*Belgium*),
J. Den Boer (*The Netherlands*), T. Dinan (*Ireland*), E. Eriksson (*Sweden*),
N. Fineberg (*United Kingdom*), T. Higuchi (*Japan*), S.H. Kennedy (*Canada*),
J.P. Lépine (*France*), M. Maj (*Italy*), A.A. Mathé (*Sweden*),
J. Mendlewicz (*Belgium*), H.J. Möller (*Germany*), S. Pallanti (*Italy*),
G. Papadimitriou (*Greece*), G. Papakostas (*USA*), Z. Rihmer (*Hungary*),
A.F. Schatzberg (*USA*), D.J. Stein (*South Africa*), T. Suppes (*USA*), E. Vieta (*Spain*),
L. Von Knorring (*Sweden*), D. Winkler (*Austria*),
S. Yamawaki (*Japan*), J. Zohar (*Israel*)

IMPORTANT ADDRESSES

Organizing Secretariat



Publi Créations

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: ifmad@publiccreations.com - Website: www.ifmad.org

Forum Venue



HILTON Hotel

Hess Andràs tér 1-3, Budapest
Hungary H-1014

Ph. 36-1-889-6600 Fax 36-1-889-6644

CONTENTS



SCIENTIFIC COMMITTEE **2**

IMPORTANT ADDRESSES **2**

FORUM VENUE **4**

WELCOME LETTER / ACKNOWLEDGEMENT **5**

PROGRAMME OVERVIEW **6**

SCIENTIFIC PROGRAMME **7/11**

POSTERS **12/18**

SCIENTIFIC INFORMATION **19**

GENERAL INFORMATION **20/21**

ANNOUNCEMENT OF NEXT FORUM **23**


Website:

www.ifmad.org 



FORUM VENUE

Ballroom Level



- **Ballroom:** Scientific Sessions
- **Ballroom Foyer:** Exhibition, Secretariat, Coffee Breaks

WELCOME LETTER



It is our pleasure to welcome you in Budapest to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD)

IFMAD has become an important Forum for the exchange of ideas on the latest developments in psychiatric treatments where international experts can address in an informal atmosphere some of the important topics in the field of mood and anxiety disorders. The meetings are particularly valued for the high quality of the scientific contributions and the opportunity for focused discussion of new data presented in a constructive and productive environment.

Attendees at previous meetings have appreciated the very efficient and agreeable formula provided by IFMAD meetings for keeping up to date with current treatment issues. We look forward to renewing old acquaintances at the next meeting, which will be held in Barcelona (7-9 November 2012) and to welcoming an even wider international audience.

We are pleased to welcome you in Budapest and have you with us again this year.

Siegfried Kasper,
Chairman

Stuart A. Montgomery,
Co-Chairman

ACKNOWLEDGEMENT

*The Organizing Committee expresses its gratitude
for their contribution of unrestricted educational grants*

Lundbeck A/S
Pierre Fabre Medicaments
Dr. Willmar Schwabe GmbH & Co. KG.

for their contribution as Sponsor of Symposia

Wisepress LTD
for its participation in the exhibition



PROGRAMME OVERVIEW

Wednesday, November 09	Thursday, November 10	Friday, November 11
	09.00/10.30 Advances in treatment of MDD to Depression	09.00/10.30 Treatment of resistant disorders
	10.30/11.00 <i>Coffee break</i>	10.30/11.00 <i>Coffee break</i>
	11.00/12.30 Why are there so few new psychotropics?	11.00/12.30 Advances with herbal remedies
	12.30/13.30 <i>Lunch</i>	12.30/13.30 <i>Lunch</i>
	13.30/15.00 Advances in the therapy of treatment resistance	13.30/15.00 Hot topics
14.30/16.00 Treatment of alcohol dependence	15.00/16.00 Debate: The amine hypothesis is a dead end for drug development	15.00/16.30 Dilemmas in bipolar disorder
16.00/16.30 <i>Coffee break</i>	16.00/16.30 <i>Coffee break</i>	
16.30/18.00 Depression and anxiety: treating the difficult patient	16.30/18.00 Multidimensional Interactions in Depression	
18.00/19.00 <i>Opening Ceremony</i>		



WEDNESDAY, 09 November 2011

14.30-16.00 SO 01 TREATMENT OF ALCOHOL DEPENDENCE

Chair: ***Siegfried Kasper (Austria),
Zoltán Rihmer (Hungary)***

14.30-14.55 SO 0101 Which target: prevention of relapse
in abstinence or reduction of alcohol intake?

Henri-Jean Aubin (France)

14.55-15.20 SO 0102 Alcohol dependence and depression
Julia Sinclair (UK)

15.20-15.45 SO 0103 A potential new treatment for alcohol
dependence

Hannu Alho (Finland)

15.45-16.00 Discussion

16.00-16.30 Coffee break

16.30-18.00 SO 02 DEPRESSION AND ANXIETY: TREATING THE DIFFICULT PATIENT

Chair: ***Zoltán Rihmer (Hungary)***

Chairman's introduction

SO 0201 The shy and anxious
Daniel Meron (UK)

Background
Case study with voting
Treatment approaches

SO 0202 The poor responder
Hamish McAllister-Williams (UK)

Background
Case study with voting
Treatment approaches

Chairman's conclusion

***Symposium sponsored by an unrestricted
educational grant from H. Lundbeck A/S***

18.00-19.00 Opening Ceremony



THURSDAY, 10 November 2011

09.00-10.30 SO 03 ADVANCES IN TREATMENT OF MDD TO DEPRESSION

Chair: **Julia Sinclair (UK),
Elias Eriksson (Sweden)**

09.00-09.25 SO 0301 Depression in schizophrenia
Istvan Bitter (Hungary)

09.25-09.50 SO 0302 Risks and Benefits of Atypical Antipsychotics
in the treatment of GAD
Borwin Bandelow (Germany)

09.50-10.15 SO 0303 Atypicals in the treatment of MDD
- advantages and risks
Hans-Jürgen Möller (Germany)

10.15-10.30 Discussion

10.30-11.00 **Coffee break**

11.00-12.30 SO 04 WHY ARE THERE SO FEW NEW PSYCHOTROPICS?

Chair: **Hans-Jürgen Möller (Germany),
Istvan Bitter (Hungary)**

11.00-11.25 SO 0401 Has the demand for evidence in psychiatry
become counterproductive?
Elias Eriksson (Sweden)

11.25-11.50 SO 0402 Economic barriers to developing new treatments
Anders Gersel Pedersen (Denmark)

11.50-12.15 SO 0403 Sunset on new psychotropics in Europe
Stuart Montgomery (UK)

12.15-12.30 Discussion

12.30-13.30 **Lunch**



13.30-15.00 **SO 05 ADVANCES IN THE THERAPY OF TREATMENT RESISTANCE**

Chair: **Daniel Souery (Belgium),
Pierre Blier (Canada)**

13.30-13.55 SO 0501 Is personalised gene targeted therapy in resistant depression possible?

Alessandro Serretti (Italy)

13.55-14.20 SO 0502 Recent advances in treatment-resistant generalized anxiety disorder

David Baldwin (UK)

14.20-14.45 SO 0503 Novel treatment of resistant depression

Daniel Souery (Belgium)

14.45-15.00 Discussion

15.00-16.00 **SO 06 DEBATE: THE AMINE HYPOTHESIS IS A DEAD END FOR DRUG DEVELOPMENT**

Chair: **Stuart Montgomery (UK)**

Pro: **Timothy Dinan (Ireland)**

Contra: **Mike Briley (France)**

16.00-16.30 **Coffee break**

16.30-18.00 **SO 07 MULTIDIMENSIONAL INTERACTIONS IN DEPRESSION**

Chair: **Siegfried Kasper (Austria)**

16.30-16.55 SO 0701 The challenges posed by ethnic and cultural diversity in the treatment of depressed patients

Driss Moussaoui (Morocco)

16.55-17.20 SO 0702 Drug-drug interactions in polymedicated depressed patients

Sheldon Preskorn (USA)

17.20-17.45 SO 0703 The clinical importance of monoamine interactions in antidepressant therapy

Pierre Blier (Canada)

17.45-18.00 Discussion

Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments



FRIDAY, 11 November 2011

09.00-10.30 SO 08 TREATMENT OF RESISTANT DISORDERS

Chair: **Naomi Fineberg (UK),
Giulio Perugi (Italy)**

09.00-09.25 SO 0801 Antidepressant-resistance in unipolar and bipolar depression
Zoltán Rihmer (Hungary)

09.25-09.50 SO 0802 Treatment for resistant OCD
Naomi Fineberg (UK)

09.50-10.15 SO 0803 Prevention of PTSD - does a window of opportunity exist?
Joseph Zohar (Israel)

10.15-10.30 Discussion

10.30-11.00 Coffee break

11.00-12.30 SO 09 ADVANCES WITH HERBAL REMEDIES

Chair: **Joseph Zohar (Israel),
Siegfried Kasper (Austria)**

11.00-11.25 SO 0901 Is lavender an anxiolytic?
Siegfried Kasper (Austria)

11.25-11.50 SO 0902 Who benefits from St. John's Wort?
Markus Gastpar (Germany)

11.50-12.15 SO 0903 Mood and Anxiety Symptoms in Dementia: The Effects of Ginkgo biloba
Ralf Ihl (Germany)

12.15-12.30 Discussion

Symposium sponsored by an unrestricted educational grant from Dr. Willmar Schwabe GmbH & Co. KG.

12.30-13.30 Lunch



13.30-15.00 SO 10 HOT TOPICS

Chair: **Jules Angst (Switzerland),
Allan Young (UK)**

13.30-13.55 SO 1001 New Directions in insomnia therapeutics
Tom Roth (USA)

13.55-14.20 SO 1002 Branded and Generic medications -
Are they interchangeable?
Ruth Baruch (USA)

14.20-14.45 SO 1003 Why do clinical trials fail?
Learning from Computer Administered Assessments
Gary Sachs (USA)

14.45-15.00 Discussion

15.00-16.30 SO 11 DILEMMAS IN BIPOLAR DISORDER

Chair: **Gary Sachs (USA),
Markus Gastpar (Germany)**

15.00-15.25 SO 1101 When is depression bipolar?:
implications for treatment
Allan Young (UK)

15.25-15.50 SO 1102 Epidemiology of bipolar spectrum disorders
beyond DSM-IV: new results from the Zurich Study
Jules Angst (Switzerland)

15.50-16.15 SO 1103 Evidence for treatment of bipolar spectrum
Giulio Perugi (Italy)



P 01. Anxiety and religiosity: Negative associations among Arab adolescents and young adults
A.M. Abdel-Khalek

Department of Psychology College of Social Sciences University of Kuwait, Kuwait

P 02. Family Constellations in Therapy-Resistant Cases of Patients Suffering from Depression and a wish to die

M. Asztalos¹, M. Angster², I. Pusztai³

¹Semmelweis University, Budapest; ²Clinical psychologist, Budapest, ³Family Constellation Therapist, Budapest, Hungary

P 03. Quick Connection: The Growing Danger of Using Designer Drugs by Depressed Adolescents Browsing Internet in Hungary

M. Asztalos¹, M. Angster², I. Pusztai³

¹Semmelweis University, Budapest; ²Clinical psychologist, Budapest; ³Family Constellation Therapist, Budapest, Hungary

P 04. Continuity of outpatient treatment after discharge of patients with major depressive disorder

W.M. Bahk¹, M.D. Kim², C.H. Kim³, Y.J. Kwon⁴, B.H. Yoon⁵

¹Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul; ²Department of Psychiatry, School of Medicine and Institute of Medical Science, Cheju National University, Jeju; ³Departments of Psychiatry, Yonsei University College of Medicine, Seoul; ⁴Department of Neuropsychiatry, Soonchunhyang University, College of Medicine, Cheonan, ⁵Department of Psychiatry, Naju National Hospital, Naju, South Korea

P 05. Predicting factors associated with drug compliance in psychiatric outpatients of a university hospital

W.M. Bahk, T.Y. Jun, K.S. Kim, W.S. Woo

Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

P 06. Adjunctive tianeptine for partial or nonresponders to selective serotonin reuptake inhibitor treatment in major depressive disorder

W.M. Bahk¹, Y.M. Jae², D.I. Jon³, K.J. Min⁴, K.C. Paik⁵, B.H. Yoon⁶

¹Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul; ²Department of Psychiatry, Bong Seng Hospital, Busan; ³Department of Psychiatry, College of Medicine, Hallym University, Anyang; ⁴Department of Psychiatry, Dankook University Hospital, Cheonan; ⁵Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul; ⁶Department of Psychiatry, Naju National Hospital, Naju, South Korea

P 07. Does mirtazapine make diabetes worse in the diabetic patient?

W.M. Bahk, T.Y. Jun, K.S. Kim, H.R. Song, H.R. Wang, Y.S. Woo

Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

P 08. Comparison of Atypical Antipsychotics Discontinuation Rate in Acute Phase Hospitalized Patients-Retrospective Chart Review Study

W.M. Bahk, C. Hahn, T.Y. Jun, K.S. Kim, Y.S. Woo

Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

P 09. Brain Tissue Loss in Children with Trichotillomania: Voxel-based Morphometry and Diffusion Tensor Studies

G.H. Bahn¹, G.H. Jahng², J. Lee³, S.Y. Shin²

¹Department of Psychiatry, Kyung Hee University Hospital, Seoul; ²Department of Radiology, Kyung Hee University, University Hospital, Seoul; ³Department of Psychiatry, Ilsin Christian Hospital, Busan, South Korea



P 10. Effect of Amitraz on anxiety-like behaviors of pregnant mice and its male offspring
A. Bakhtiari¹, M. Dooraghi¹, B. Shahsavari¹, J. Solati²

¹Department of Microbiology, Faculty of Science, Karaj Branch, Islamic Azad University, Alborz, Iran, Karaj, Iran; ²Department of Biology, Islamic Azad University-Karaj Branch, Karaj, Alborz, Iran

P 11. Activity of atypical antipsychotics in elevated plus-maze test in rats

P. Bieñkowski¹, M. Jastrzębska-Więsek², M. Kołaczkowski^{2,3}, P. Mierzejewski¹, A. Partyka², A. Wasik², A. Wesołowska²

¹Institute of Psychiatry and Neurology, Warszawa; ²Jagiellonian University Medical College, Kraków; ³Adamed Pharmaceuticals, Pieńków, Poland

P 12. EMD 386088 produces anxiolytic-like activity in rats via stimulation of 5-HT6 receptors

P. Bieñkowski¹, M. Jastrzębska-Więsek², M. Kołaczkowski^{2,3}, P. Mierzejewski¹, A. Partyka², A. Siwek², A. Wasik², A. Wesołowska²

¹Institute of Psychiatry and Neurology, Warszawa; ²Jagiellonian University Medical College, Kraków; ³Adamed Pharmaceuticals, Pieńków, Poland

P 13. Major Depressive Disorder (MDD) Severity and the Frequency of Painful Physical Symptoms (PPS): a Pooled Analysis of Observational Studies

A. Brnabic¹, A. Lenox-Smith², C. Lin³, S. Nery⁴, H. Duenas⁵, Z. Kadziola⁶, J. Raskin⁷

¹Eli Lilly, Australia; ²Eli Lilly, UK; ³Eli Lilly, Taiwan; ⁴Eli Lilly, Brazil; ⁵Eli Lilly, Mexico; ⁶Eli Lilly, Austria; ⁷Eli Lilly, Canada

P 14. Is the «behavioral variant frontotemporal dementia phenocopy syndrome» a subtype of bipolar disorder specific of the elderly?

E. Chinea Cabello¹, J. Barroso Rival¹, A. Hernández Dorta², J. Rojo³, P. Velasco Rodríguez-Solís³

¹Hospital Universitario de Canarias, Mental Health, La Laguna, Santa Cruz de Tenerife; ²Hospital Universitario de Canarias, Neurology, La Laguna, Santa Cruz de Tenerife; ³School of Psychology, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Spain

P 15. Prevalence, Medical burden and Quality of life of Anxiety disorders in South Korea
H.W. Lee¹, M.J. Cho², S.M. Jang³, H.J. Jeon⁴, J.Y. Lee¹, H.Y. Jung¹

¹Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul; ²Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul; ³Department of Psychiatry, Kyungpook National University Hospital, Daegu; ⁴Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

P 16. Smoking related depression is depended on early life experiences and determines quitting outcomes

I. Csala, P. Dome, E. Egervari, G. Faludi, J. Lazary

Department of Clinical and Theoretical Mental Health, Budapest, Hungary

P 17. Gender aspects of insomnia

Z. Dole

Psychiatrist, Private-Practice, Women Mental-Health, Herzelia, Israel

P 18. Comparison of two groups of patients with fibromyalgia and affective disorders

J.A. Dorado Primo¹, C. Balmon Cruz¹, L. Dorado Balmon²

¹Psychiatrists, Mental Health Clinic Management Unit, Andalusian Health Service, Córdoba; ²Psychology, Seville University, Spain



P 19. The Impact of Financial Crisis on Depression and Anxiety: Evidence from a Depression Telephone Helpline

M. Economou^{1,2}, A. Komporozos¹, E. Louki¹, L. Peppou¹, C. Stefanis¹, C. Theleritis¹

¹University Mental Health Research Institute (UMHRI), Athens; ²First Department of Psychiatry, Medical School, University of Athens, Athens, Greece

P 20. Increased suicidality in Greece linked to depression

M. Economou¹, M.G. Madianos², L. Peppou¹, C. Stefanis¹, C. Theleritis¹

¹University Mental Health Research Institute (UMHRI), Athens; ²Department of Mental Health & Behavioural Sciences, School of Health Sciences, University of Athens, Athens, Greece

P 21. Quetiapine fumarate extended release (XR) in bipolar depression and major depressive disorder

H. Eriksson¹, W. Earley², U. Gustafsson¹

¹AstraZeneca R&D, Södertälje, Sweden; ²AstraZeneca Pharmaceuticals LP, Wilmington, USA

P 22. Influence of cognitive insight on the effectiveness of psychoeducation in bipolar patients

K. Eung-jo, K. Imyeol, I. Sohn

Keyo Hospital, Uiwang City, South Korea

P 23. Transcranial direct current stimulation (tDCS) a treatment for depressive illness

R. Ferrucci^{1,2}, M. Bortolomasi³, M. Fumagalli^{1,2}, M. Giacomuzzi³, F. Mameli¹, A. Priori^{1,2}, E. Scelzo^{1,2}, M. Vergari¹

¹Centro Clinico per la Neurostimolazione, le Neurotecnologie ed i Disordini del Movimento, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Università degli Studi di Milano, Milan, Italy; ³Unità Operativa di Psichiatria, Ospedale Villa Santa Chiara, Verona, Italy

P 24. The role of birth season in personality and pathology: time of birth is associated with affective temperaments in a general student population

X. Gonda^{1,2}, Z. Rihmer¹, K.N. Fountoulakis³, M. Pompili⁴, G. Vazquez⁵, P. Erdos⁶, M. Ormos⁶

¹Department of Clinical and Theoretical Mental Health, Kutvolgyi Clinical Center, Semmelweis University, Budapest, Hungary; ²Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; ³3rd Department of Psychiatry, Aristotle University, Thessaloniki, Greece; ⁴Department of Psychiatry, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy; ⁵Department of Neuroscience, University of Palermo, Buenos Aires, Argentina; ⁶Department of Finance, Budapest University of Technology and Economics, Budapest, Hungary

P 25. Treatment response to agomelatine in depressed patients previously treated or not by an antidepressant (d-change study)

P. Gorwood¹, L. Laigle², G. Vaiva³, P. Courtet⁴, F. Bayle¹, E. Corruble⁵, P.M. Llorca⁶

¹University Paris Descartes, Paris; ²IRIS, France; ³University Lille, Lille; ⁴University Montpellier, Montpellier; ⁵University Paris Sud, Paris; ⁶University Auvergne, Auvergne, France

P 26. Early trauma and platelet brain-derived neurotrophic factor (BDNF) after three month follow-up in patients with major depressive disorder

J.J. Hong¹, K. Eun-Suk Kang², H.L. Eun³, W.L. Sun³, G.J. Seul¹, J. Eu-Gene¹, J. Ju-Ri¹, L. Dongsoo^{1,3}

¹Department of Psychiatry, ²Depression Center, Samsung Medical Center, ³Sungkyunkwan University School of Medicine, Seoul, South Korea

P 27. Investigation of the absorption profile of Lu AA21004

A.M. Højer, B. Søgaard, J. Areberg

H. Lundbeck A/S, Valby, Denmark



P 28. The Impact of Religiosity, Spirituality on Depression & Quality of Life in Solitary Elderly in a Korean Area

Y. Huh, D.I. Jeon, D.H. Kim, Y.S. Moon

Hallym Medical Center, Hallym University, Chuncheon, South Korea

P 29. Agomelatine (Valdoxan) in clinical practice: results from the Russian observational program CHRONOS.

S.V. Ivanov, M.A. Samuchia

National Mental Health Research Center of Russian Medical Academy, Moscow, Russia

P 30. Correlations between serum C-reactive protein levels and symptoms of bipolar mania and schizophrenia

Y.M. Jae

Department of Psychiatry, Bong Seng Hospital, Busan, South Korea

P 31. Influence of eating attitude and being ostracized on depressive symptoms among high school students in Korea

Y.M. Jae¹, M.D. Kim², Y.J. Kwon³, B.H. Yoon⁴

¹Department of Psychiatry, Bong Seng Hospital, Busan; ²Department of Psychiatry, Jeju National University School of Medicine, Jeju; ³Department of Neuropsychiatry, Soon Chun Hyang University, College of Medicine, Cheonan; ⁴Department of Psychiatry, Naju National Hospital, Naju, South Korea

P 32. Transcranial Bright Light Treatment via Ear Canals in Seasonal Affective Disorder (SAD) a Randomized Controlled Study

H. Jurvelin¹, J. Jokelainen^{2,4}, J. Nissilä², P. Räsänen^{1,5}, T. Takala³, M. Timonen²

¹University of Oulu, Institute of Clinical Medicine, Department of Psychiatry, University of Oulu, Oulu; ²University of Oulu, Institute of Health Sciences, University of Oulu, Oulu; ³Oulu Deaconess Institute, Oulu; ⁴Unit of General Practice, Oulu University Hospital, Oulu; ⁵Oulu Health Centre, Oulu, Finland

P 33. Changes of Cholesterol Level and Impulsiveness after Pharmacologic treatments in Patients with Bipolar Disorder

S.H. Kang¹, M.Y. Chung²

¹Department of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea; ²Department of Neuropsychiatry, Seoul Veterans Hospital, Seoul, South Korea

P 34. Influence of eating attitude and being ostracized on depressive symptoms among elementary and middle school students in Korea

M.D. Kim¹, Y.M. Jae², B.H. Yoon³, Y.J. Kwon⁴

¹Department of Psychiatry, Jeju National University School of Medicine; ²Department of Psychiatry, Bong Seng Hospital, Busan; ³Department of Psychiatry, Naju National Hospital, Naju, South Korea; ⁴Department of Psychiatry, Soon Chun Hyang University, College of Medicine, Cheonan, South Korea

P 35. Development of a Computer Based Symmetry and Arrangement Symptoms Measures in Obsessive-Compulsive Disorder

C.H. Kim¹, K. Kim², D. Roh¹

¹Department of Psychiatry, Yonsei University College of Medicine, Seoul; ²Department of Biomedical Engineering, Hanyang University, Seoul, South Korea

P 36. Pharmacotherapy of depressive disorder - treatment decision after occurrence of diarrhea

O. Kozumplik¹, S. Uzun¹, M. Jakovljevic^{2,3}

¹University Department, Clinic for Psychiatry Vrapce, Zagreb; ²University Department, Clinical Hospital Zagreb; ³School of Medicine, University of Zagreb, Croatia



P37. The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of bipolarity: preliminary study

S.H. Lee, Y.M. Park

Inje University, Goyang, South Korea

P38. Efficacy of duloxetine vs venlafaxine – an updated non-inferiority analysis in Major Depressive Disorder

A. Lenox-Smith¹, K. Kelin², A. Brnabic²

¹Eli Lilly & Company Ltd, Basingstoke, UK; ²Eli Lilly, Sydney, Australia

P39. A US retrospective database analysis evaluating characteristics of patients with bipolar disorder prior to initiating treatment with immediate-release (IR) or extended-release (XR) quetiapine fumarate

J.C. Locklear¹, B. Alemayehu¹, R.S. Brody¹, W.R. Earley¹, S. Kamat³, D. Kern³, H. Svedsäter², O. Tunceli³

¹AstraZeneca Pharmaceuticals LP, Wilmington, USA; ²AstraZeneca R&D, Mölndal, Sweden; ³HealthCore Inc, Wilmington, USA

P40. Atomoxetine influence on aggressive behavior in mice model of social interaction

A. Machalova^{1,2}, K. Slais², A. Sulcova²

¹Masaryk University, Brno, Faculty of Medicine, Department of Pharmacology, Brno; ²CEITEC (Central European Institute of Technology) - Masaryk University, Brno, Brno, Czech Republic

P41. Zinc deficiency and hyperactivation of HPA axis in treatment resistant depression

K. Mlyniec^{1,3}, B. Budziszewska^{2,3}, U. Doboszevska³, G. Nowak^{1,3}, W. Reczyński⁴

¹Department of Pharmacobiology, Jagiellonian University Medical College, Kraków; ²Department of Toxicology, Jagiellonian University Medical College, Kraków; ³Institute of Pharmacology, Polish Academy of Sciences and Center of Excellence in Neuropsychopharmacology, Kraków; ⁴Faculty of Material Science and Ceramics, AGH University of Science and Technology, Kraków, Poland

P42. Efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) in elderly patients with major depressive disorder (MDD) according to baseline anxiety symptoms, sleep disturbance and pain levels

S. Montgomery¹, A.C. Altamura², H. Katila³, C. Datto⁴, J. Szamosi⁵, H. Eriksson⁵

¹Emeritus Professor of Psychiatry, Imperial College, University of London, London, UK; ²Department of Psychiatry, University of Milan, Milan, Italy; ³Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland; ⁴AstraZeneca Pharmaceuticals, Wilmington, USA; ⁵AstraZeneca R&D, Södertälje, Sweden

P43. The perception of an oral dispersible escitalopram tablet in a comparative bioavailability study

D. Nilausen¹, R. Linde¹, J. vanGerven²

¹H. Lundbeck A/S, Copenhagen, Denmark; ²CHDR, Leiden, The Netherlands.

P44. Agomelatine in depression treatment, multicentre study in Slovakia

V. Novotný, J. Pečenák

Clinic of Psychiatry, Comenius University, Bratislava, Slovakia

P45. The Viennese psychiatric intensive care unit

E. Pjrek¹, R. Frey¹, A. Höflich¹, A. Naderi-Heiden¹, A. Strnad¹, J. Scharfetter², S. Kasper¹

¹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; ²Department of Psychiatry, Social Medical Center East, Vienna, Austria

P46. Bupropion in Depression - (Case Report)

G. Racetovic

Community Mental Health Center, Health Center, Prijedor, Republic of Srpska, Bosnia and Herzegovina



P 47. Sedation intensity during dose escalation of quetiapine XR or IR in bipolar depression: a multicenter, double-blind, randomized, phase IV study

R. Riesenber¹, C. Datto²

¹Atlanta Center for Medical Research, Atlanta, USA; ²AstraZeneca Pharmaceuticals, Wilmington, USA

P 48. Duloxetine: Treatment of Depressive Patients In a Consulting Department

J.L. Rodriguez Calvin

Hospital de Fuenlabrada, Madrid, Spain

P 49. Early antidepressant switch in MDD with pain symptoms: functional improvement

I. Romera¹, I. Gilaberte¹, V. Perez², J.M. Menchon³, R. Papen⁴, A. Schacht⁴, D. Neuhauser⁵, M. Abbar⁶, H. Picard⁷

¹Eli Lilly and Company Madrid Spain; ²Hospital de Sant Pau i de la Santa Creu, UAB, CIBERSAM, Barcelona, Spain; ³Hospital Universitari de Bellvitge, CIBERSAM, Hspitalet de Llobregat, Barcelona, Spain; ⁴Eli Lilly and Company, Bad Homburg, Germany; ⁵Eli Lilly and Company, Vienna, Austria; ⁶Hospital Caremau, Nimes, France; ⁷Unite INSERM UMR S894 Saint-Anne Hospital, Paris, France

P 50. A Randomised Controlled Study of Ultra-brief Electroconvulsive Therapy at Eight Times Seizure Threshold

I. Schweitzer, D. Smith, A. Ingram, N. Katalinic, C. Loo

Departments of Psychiatry, University of Melbourne & University of New South Wales, Australia

P 51. Antidepressant-like activity of EMD 386088, a potent 5-HT₆ receptor agonist, and its positive interaction with imipramine in the rat forced swim test

A. Siwek¹, M. Jastrzębska-Więsek², M. Kołaczowski³, A. Partyka², A. Wesołowska², D. Wróbel²

¹Department of Pharmacobiology, Jagiellonian University Medical College, Krakow; ²Department of Clinical Pharmacy, Jagiellonian University Medical College, Krakow; ³Department of Medicinal Chemistry, Jagiellonian University Medical College, Krakow, Poland

P 52. Outcomes and unmet needs in bipolar disease in real-life practice: results from a large, multinational longitudinal study (WAVEbd)

E. Vieta¹, M.L. Figueira², F. Bellivier³, D. Souery⁴, E. Blasco-Colmenares⁵, J.M. Langosch⁶, M. Moreno-Manzanaro⁷, E. Medina⁷, on behalf of the WAVE-bd Study Group

¹Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; ²Psychiatric Department, Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Lisboa, Portugal; ³Hôpital Henri Mondor, Pôle de Psychiatrie, Créteil cedex, France; ⁴Centre Européen de Psychologie Médicale / Psy-Pluriel, Brussels, Belgium; ⁵Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ⁶Bethanien Hospital for Psychiatry, Psychosomatics, and Psychotherapy, Greifswald, Germany; ⁷Medical Department, AstraZeneca Pharmaceuticals, Madrid, Spain

P 53. Rates of bipolar disease relapse/recurrence in real-life practice in WAVEbd study

E. Vieta¹, M.L. Figueira², Frank Bellivier³, D. Souery⁴, E. Blasco-Colmenares⁵, J.M. Langosch⁶, M. Moreno-Manzanaro⁷, E. Medina⁷, on behalf of the WAVE-bd Study Group

¹Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; ²Psychiatric Department, Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Lisboa, Portugal; ³Hôpital Henri Mondor, Pôle de Psychiatrie, Créteil cedex, France; ⁴Centre Européen de Psychologie Médicale / Psy-Pluriel, Brussels, Belgium; ⁵Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ⁶Bethanien Hospital for Psychiatry, Psychosomatics, and Psychotherapy, Greifswald, Germany; ⁷Medical Department, AstraZeneca Pharmaceuticals, Madrid, Spain



P 54. The impact of affective symptoms in first episode psychosis

I.P. Stoica

Mental Health Centre Timisoara, Romania

P 55. The effects of 10 mg Lu AA21004 and 30 mg mirtazapine on actual driving performance in healthy subjects

E. Theunissen¹, A.M. Hojer², J. Ramaekers¹, D. Street², A. van Oers¹

¹Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands; ²Department of Clinical Pharmacology and Translational Medicine, H. Lundbeck A/S, Lundbeck, Denmark

P 56. Transcranial Brain-Targeted Bright Light Treatment via Ear Canals in Seasonal Affective Disorder (SAD) a Pilot Study

M. Timonen¹, J. Jokelainen^{2,3}, H. Jurvelin², J. Nissilä¹, A. Aunio⁴, P. Räsänen^{2,5}, T. Takala⁶

¹University of Oulu, Institute of Health Sciences, University of Oulu, Oulu; ²University of Oulu, Institute of Clinical Medicine, Department of Psychiatry, University of Oulu, Oulu; ³Unit of General Practice, Oulu University Hospital, Oulu; ⁴Valkee Ltd., Kiilakiventie 1, Oulu; ⁵Oulu University Hospital, Department of Psychiatry, Oulu; ⁶Oulu Deaconess Institute, Oulu, Finland

P 57. Nausea during treatment of patient with depressive disorder

S. Uzun¹, O. Kozumplik¹, M. Jakovljevic^{2,3}

¹University Department, Clinic for Psychiatry Vrapce, Zagreb; ²University Department, Clinical Hospital Zagreb, Zagreb; ³School of Medicine, University of Zagreb, Zagreb, Croatia

P 58. Registry of Frequency of Mixed States in Patients with a Major Depressive Episode; Dutch part

E.M. Van Gent¹, K.D.J. Beintema²

¹Neuropsychiatrist, Director Faneurop Biological psychiatry, Arnhem, The Netherlands; ²Sanofi-aventis Netherlands BV, Medical Dep., Gouda, The Netherlands

P 59. A Survey of Patient Preferences for a Placebo Orodispersible Tablet

A. G. Wade¹, G.M. Crawford¹, D. Young²

¹CPS Research, Glasgow, United Kingdom; ²Department of Mathematics and statistics, University of Strathclyde, Glasgow, United Kingdom

P 60. Activity and the sleep-wake cycle in opioid detoxification with methadone or buprenorphine

D. Winkler¹, R. Frey¹, A. Naderi-Heiden¹, A. Strnad¹, A. Kowarik², S. Kasper¹, E. Pjrek¹

¹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; ²Data-analysis OG, Vienna, Austria

P 61. Treatment with Milnacipran is effective in patients with Seasonal Affective Disorder: Results of an open-label study

A. Konstantinidis, E. Winkler-Pjrek, D. Winkler, N. Praschak-Rieder, M. Willeit, S. Kasper

Department for Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University of Vienna, Vienna, Austria

P 62. Dysfunctional Stress Copying and Maladaptive Interpretation of Bodily Sensation in Patients with Panic Disorder

J.C. Yang¹, K.C. Paik²

¹Department of Psychiatry, Chonbuk National University Medical School, Jeonju; ²Department of Psychiatry, Dankook University School of Medicine, Cheonan, South Korea



Audio-Visual Facilities

Speakers must go to the preview room in order to validate and download their presentation files, at least forty minutes before the beginning of the sessions.

Please respect this schedule, otherwise, the performance of the received presentations is not guaranteed.

We cannot accept presentations delivered in room directly (without previewing).

Coffee breaks and midday are the busiest time in the preview room. So we recommend you to come to the preview early in the morning or during other presentations. A technician will guide and assist the speakers for checking and downloading their presentation files.

European Accreditation

15 credits have been granted for this Congress. UEMS credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.

Certificate of Attendance

A certificate of attendance is provided, on request, at the registration desk on the last day of the Forum.





GENERAL INFORMATION

The “11th International Forum on Mood and Anxiety Disorders” is held at the Hilton Hotel, Hess András tér 1-3, from 09-11 November 2011.

Admission

The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the Congress. Only badge holders are admitted to the appropriate sessions, exhibition and Welcome Cocktail.

Coffee breaks and Lunches

During the Congress session breaks, coffee breaks and lunches are served free of charge to all registered participants, wearing Congress badges.

City

The capital city of Hungary, Budapest, was created out of the unification of the separate historic towns of Buda, Pest and Óbuda in 1873. The city, bisected by the River Danube, covers an area of two hundred square miles and it is divided into 23 administrative districts, and home today to a population of 1.8 million people.

Electricity

Voltage in Hungary is 220 volts, and plugs are of the two-pin continental type.

Exchange

All visitors are advised to exchange currency only at accredited places. The majority of banks have 24-hour ATM's some of which can also exchange foreign currency. Individual banks and travel agencies are free to set their own rates (based on those advertised by the Hungarian National Bank) but they must be clearly displayed. The Hungarian currency is the forint. There are coins to the value of 1, 2, 5, 10, 20, 50 and 100 forints, and notes for 200, 500, 1,000, 2,000, 5,000, 10,000 and 20,000 forints. All the most popular credit, debit and charge cards can be used in banks and in ATM's to withdraw forints, and in hotels, restaurants and shops for purchases.

Insurance

The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants and accompanying persons, either during or as a result of the Congress. Registration does not include insurance.

Language

The official language of the Congress is English. No simultaneous translation is provided.



Secretariat

The secretariat desk will open on Wednesday, November 09th and stay open all through the Congress.

Congress as follows:

Wednesday, November 9	11h00 - 19h00
Thursday, November 10	08h00 - 18h00
Friday, November 11	08h00 - 16h00

Smoking Policy

The 11th International Forum on Mood and Anxiety Disorders wishes to be a non-smoking congress.

Useful Numbers

Airport	(+36) 1 296 9696
Luggage service T2A	(+36) 1 296 8108
Luggage service T2B	(+36) 1 295 3480
Tales Taxi	555-5555

Welcome cocktail

All delegates are cordially invited to attend the Welcome Cocktail which is held on Wednesday, 09th November at 18.00 in the Ballroom Foyer of the Hilton Hotel.



NOTES


The image shows a digital notepad interface. At the top, there is a dark blue header bar. On the left side of this bar is a white icon of a knot or a stylized letter 'A'. On the right side of the header bar, the word "NOTES" is written in white, bold, uppercase letters. Below the header bar, the main area of the page is white and contains numerous horizontal blue lines, providing space for writing notes.



ANNOUNCEMENT OF NEXT FORUM

The 12th International Forum on Mood and Anxiety Disorders

will be held in **Barcelona**, Spain
07-09 November, 2012



**New
location**



Cipralex - the power to tackle depression at its core

Leaving no one behind

Presentation Film-coated tablets 5 10 15 20 mg, oral drops, solution 10 20 mg/ml and orodispersible tablets 10 20 mg. **Indication** Treatment of major depressive episodes, Treatment of panic disorder with or without agoraphobia, Treatment of social anxiety disorder (social phobia), Treatment of generalised anxiety disorder, Treatment of obsessive compulsive disorder. **Dosage** Adults: The recommended starting dose is 10 mg once daily. Depending on individual patient response the dose may be increased to a maximum of 20 mg once daily. An initial starting dose of 5 mg once daily is recommended in the treatment of elderly (>65 years), in panic disorder and in patients with reduced hepatic function. Children and adolescents (< 18 years): Cipralex should not be used in children and adolescents under 18 years of age. Discontinuation: Discontinue gradually over a period of at least one to two weeks to reduce the possibility of discontinuation symptoms. **Contraindications** Hypersensitivity to escitalopram or any other components. In combination with MAO-inhibitors. Should not be used during pregnancy unless clearly needed and after careful consideration of the

risk/benefit ratio. Breast-feeding is not recommended. **Precautions** Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide. It is a general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stage of treatment. Close supervision of high-risk patients should accompany drug therapy. Patients (and caregivers) should be alerted about the need to monitor for emergence of suicidal behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored. SSRIs should be used with caution in patients with a history of mania/hypomania. Treatment with SSRIs may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted. The use of SSRIs/SNRIs has been associated with the development of akathisia. Hyponatraemia has been reported rarely with the use of SSRIs. There have been reports of cutaneous bleeding abnormalities. **Interactions** Caution is advised when taken in combination with MAO-inhibitors, serotonergic

medicinal products, products lowering the seizure threshold, lithium, tryptophan, St. John's Wort, oral anticoagulants or antiplatelet agents (NSAIDs), and products predominantly metabolised by the enzymes CYP2C19 and CYP2D6. **Undesirable effects** Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and frequency with continued treatment. Most commonly occurring: nausea, decreased/increase appetite, weight increased, anxiety, restlessness, abnormal dreams, anorgasmia, insomnia, somnolence, dizziness, paraesthesia, tremor, constipation, vomiting, dry mouth, diarrhoea, sweating increased, arthralgia, myalgia, ejaculation disorder, fatigue and pyrexia. **Overdose** Cases of overdose with escitalopram doses between 400 mg and 800 mg have been reported without any severe symptoms. **Legal category** POM. **Date of preparation or last review** March 2011 **Full Prescribing Information** is available from H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark